LIGR, a protease-activated receptor-2-derived peptide, enhances skin pigmentation without inducing inflammatory processes

• Published in: Pigment cell and melanoma research Vol. 21; no. 2; pp. 172 - 183
• Main Authors: Lin, Connie B., Chen, Nannan, Scarpa, Richard, Guan, Fei, Babiarz-Magee, Laura, Liebel, Frank, Li, Wen-Hwa, Kizoulis, Menas, Shapiro, Stanley, Seiberg, Miri
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.04.2008
• Subjects: Administration, Topical; Animals; Blotting, Western; Cells, Cultured; darkening; Female; Gene Silencing; Humans; Inflammation; keratinocytes; Keratinocytes - drug effects; Keratinocytes - metabolism; LIGR; Mice; Mice, SCID; PAR-2; Peptides - genetics; Peptides - pharmacology; Phagocytosis; Receptor, PAR-2 - genetics; Receptor, PAR-2 - metabolism; Reverse Transcriptase Polymerase Chain Reaction; Rho-GTP; Signal Transduction - drug effects; skin pigmentation; Skin Pigmentation - drug effects; Skin Transplantation; sunless tanning; Swine; Transplantation, Heterologous
• ISSN: 1755-1471; 1755-148X
• DOI: 10.1111/j.1755-148X.2008.00441.x

Summary The protease‐activated receptor‐2 (PAR‐2) is a seven transmembrane G‐protein‐coupled receptor that could be activated by serine protease cleavage or by synthetic peptide agonists. We showed earlier that activation of PAR‐2 with Ser‐Leu‐Ile‐Gly‐Arg‐Leu‐NH2 (SLIGRL), a known PAR‐2 activating peptide, induces keratinocyte phagocytosis and increases skin pigmentation, indicating that PAR‐2 regulates pigmentation by controlling phagocytosis of melanosomes. Here, we show that Leu‐Ile‐Gly‐Arg‐NH2 (LIGR) can also induce skin pigmentation. Both SLIGRL and LIGR increased melanin deposition in vitro and in vivo, and visibly darkened human skins grafted onto severe combined immuno‐deficient (SCID) mice. Both SLIGRL and LIGR stimulated Rho‐GTP activation resulting in keratinocyte phagocytosis. Interestingly, LIGR activates only a subset of the PAR‐2 signaling pathways, and unlike SLIGRL, it does not induce inflammatory processes. LIGR did not affect many PAR‐2 signaling pathways, including [Ca2+] mobilization, cAMP induction, the induction of cyclooxgenase‐2 (COX‐2) expression and the secretion of prostaglandin E2, interleukin‐6 and ‐8. PAR‐2 siRNA inhibited LIGR‐induced phagocytosis, indicating that LIGR signals via PAR‐2. Our data suggest that LIGR is a more specific regulator of PAR‐2‐induced pigmentation relative to SLIGRL. Therefore, enhancing skin pigmentation by topical applications of LIGR may result in a desired tanned‐like skin color, without enhancing inflammatory processes, and without the need of UV exposure.